Gilead Sciences is a biopharmaceutical company, focusing on medicines to prevent and treat diseases, including HIV, viral hepatitis and cancer. Co.'s products include: Biktarvy®, which is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), an injection for intravenous use, which is a nucleotide analog RNA polymerase inhibitor indicated for certain patients for the treatment of COVID-19 requiring hospitalization; and Epclusa®, which is an oral formulation of a once-daily single tablet regimen of sofosbuvir and velpatasvir for the treatment of chronic hepatitis C virus (HCV) infection in adults and certain pediatric patients. When considering the Gilead Sciences Inc stock dividend history, we have taken known splits into account, such that the GILD dividend history is presented on a split-adjusted ("apples to apples") basis. Gilead Sciences Inc dividend history is presented both in graphical/chart form, and as a GILD dividend history data table along the right-hand column.
|
GILD Stock Dividend HistoryThe GILD dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable GILD historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the GILD dividend history record. Also see the GILD stock dividend history data table along the right-hand column below. |
|
GILD Next Dividend Date » (Projection based upon history) GILD Dividend Growth Rate » Quotes delayed 20 minutes |
Buy (2.83 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Analysts' Target Price: GILD Forecast Based on data provided by Zacks Investment Research via Quandl.com |
Projection: GILD Next Dividend Date Chart: GILD Chart - 5Yr Dividend Yield |